Burtomab -I-131 - Y-mAbs Therapeutics

Drug Profile

Burtomab -I-131 - Y-mAbs Therapeutics

Alternative Names: 131 I-8H9; 8H9 MAb; 131I 8H9 (B7-H3); Iodine I 131 monoclonal antibody 8H9; Mab 131-I labelled 8H9

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer Memorial Sloan-Kettering Cancer Center; Y-mAbs Therapeutics
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action CD antigen modulators; Immunostimulants; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma; Carcinomatous meningitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Carcinomatous meningitis; Neuroblastoma
  • Phase I/II Soft tissue sarcoma
  • No development reported Peritoneal cancer; Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Peritoneal-cancer(Recurrent, Second-line therapy or greater) in USA (Intraperitoneal)
  • 12 Sep 2017 Y-mAbs Therapeutics plans a phase II trial for Neuroblastoma (In children, In adolescents, In adults) (NCT03275402)
  • 07 Jun 2017 Burtomab -I-131 - Y-mAbs Therapeutics receives Breakthrough Therapy status for Neuroblastoma (Second-line therapy or greater, Metastatic disease, In neonates, In infants, In children) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top